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Xenotropic MLV-Related Virus (XMRV) was recently reported to be associated with prostate cancer and chronic fatigue syndrome
(CFS). Infection was also reported in 3.7% of healthy individuals. These highly reported frequencies of infection prompted
concerns about the possibility of a new, widespread retroviral epidemic. The Multicenter AIDS Cohort Study (MACS) provides
an opportunity to assess the prevalence of XMRV infection and its association with HIV-1 infection among men who have sex
with men. Reliable detection of XMRV infection requires the application of multiple diagnostic methods, including detection of
human antibodies to XMRV and detection of XMRV nucleic acid. We, therefore, tested 332 patient plasma and PBMC samples
obtained from recent visits in a subset of patients in the MACS cohort for XMRV antibodies using Abbott prototype ARCHITECT
chemiluminescent immunoassays (CMIAs) and for XMRV RNA and proviral DNA using a XMRV single-copy qPCR assay (X-
SCA). Although 9 of 332 (2.7%) samples showed low positive reactivity against a single antigen in the CMIA, none of these
samples or matched controls were positive for plasma XMRV RNA or PBMC XMRV DNA by X-SCA. Thus, we found no evidence
of XMRV infection among men in the MACS regardless of HIV-1 serostatus.
1.Introduction
Xenotropic Murine Leukemia Virus-Related Virus (XMRV)
isarecentlydiscoveredgammaretrovirusreportedlyassociat-
ed with prostate cancer and chronic fatigue syndrome (CFS)
[1, 2]. Urisman et al. ﬁrst identiﬁed XMRV in 2006 in a
cohort of prostate cancer patients [2], followed by Lombardi
et al. who reported XMRV infection in 67% of patients with
severe CFS and 3.7% of healthy individuals [1]. These initial
reportsprovidedacompellingrationaleforfurtherinvestiga-
tionsintotheprevalenceofXMRVinfectioninhumanpopu-
lations. However, controversy arose when subsequent studies
failed to detect the virus in similar cohorts [3–7]. It was sug-
gested that inconsistencies in detection of XMRV in patient
samples could result from varied incidence of infection in
diﬀerent populations, diﬀering criteria for patient selection,
and diﬀering detection methods [8]. It was also proposed
that virus levels may be chronically low or episodic in patient
plasma or tissues, making virus detection diﬃcult [8]. Ad-
ding to the complexity, detection of XMRV by PCR is highly
susceptible to false positive results due to ampliﬁcation of
closely related endogenous Murine Leukemia Viruses
(MLVs) in the mouse genome and the high prevalence of
contaminatingmousegenomicDNAinmanyspecimensand
reagents [9, 10]. Additionally, studies have suggested that
XMRV detection is the result of laboratory contamination
frominfectedcelllines[11–14].Paprotkaetal.proposedthat
XMRV originated as a laboratory artifact when two endoge-
nous mouse proviruses recombined during passaging of a
human prostate cancer tumor in nude mice, an event that2 Advances in Virology
is highly unlikely to have occurred more than once. The
authors, therefore, concluded that published XMRV sequen-
cesobtainedfrompatientsamplesmusthavecomefromcon-
taminationofsamplesbyvirusorDNAfromcelllinesinfect-
ed with this recombinant virus [14]. To investigate the hu-
man prevalence of XMRV infection, it is clear that reliable
detectionrequirestheapplicationofseveraldiagnosticmeth-
ods used together, including methods that are not inﬂuen-
ced by nucleic acid contamination, to avoid reporting poten-
tially high rates of false positives.
Accordingly, we analyzed recently collected blood sam-
ples from participants in the MACS cohort using new tests
that detect XMRV antibodies and nucleic acid in the blood
stream [15]. The MACS cohort provided the opportunity to
assess the association of XMRV with HIV-1 infection and
other clinical outcomes and to evaluate its possible mode of
transmission. We hypothesized that the prevalence of XMRV
infection is higher among men who have acquired HIV-1
infection than among seronegative controls. Previous studies
have evaluated samples from HIV-infected cohorts for the
presence of XMRV nucleic acid with negative results [7, 16,
17], but none has looked for the presence of antibody to
XMRV.
In the current study, we ﬁrst screened samples for anti-
body reactivity to XMRV. This approach eliminated the risk
that positive results were due to nucleic acid contamination
and mitigated the risk that infection would be missed due to
low-level or episodic viremia. To further minimize the risk of
reporting false-positive XMRV infection status, we required
that antibody and nucleic acid (either viral RNA or DNA)
mustbothbepresenttoreportthepatientasbeingXMRVin-
fected. These criteria are supported by studies performed on
XMRV-inoculated macaques conﬁrming that both antibody
and nucleic acid are readily detectable in longitudinal blood
samples collected after XMRV infection (Kearney et al. in
press; Del Prete et al. in preparation) [15, 18]. Plasma sam-
ples from the MACS cohort were screened for antibody
reactivitybyCMIAsandconﬁrmedbyWesternblot.Reactive
samples and blinded, matched antibody negative controls
from the same cohort were then tested for the presence of
XMRV RNA in plasma and proviral DNA in PBMCs. This
approach to determine the prevalence of XMRV infection
minimizes the risk of reporting false positives that occur
from either cross-reactive antibodies in the bloodstream or
contaminating nucleic acid in samples or reagents.
2. Methods
2.1. Clinical Samples. Plasma and PBMC samples were ob-
tained from332 individuals in the MACScohort. Allsamples
were collected from clinical visits in 2006–2009. Half of the
332 men were HIV-1 seropositive, of whom 89 were users of
antiretroviral therapy (ART) and 77 were ART na¨ ıve. HIV-1-
seronegative men of similar age, date of study entry, center,
and hepatitis status were selected from the same visits as the
HIV-1-seropositive men. The median age (interquartiles
(25%, 75%)) of both the HIV-1-seropositive and -seronega-
tive men was 50 years (45, 55.5), and the median (IQR) CD4
cell count and HIV-1 RNA levels of the HIV-1 seropositives
were 578 (418, 786) cells/mm3 and <50 (<50, 12408) copies/
mL, respectively. Plasma samples were screened at Abbott
Laboratories for the presence of XMRV antibodies by newly
developed XMRV CMIAs (ARCHITECT platform) [15].
Samples with positive CMIA results were tested by Western
blot[15].SamplesthatwerepositiveforXMRVantibodiesby
CMIA were matched 1:3 by age, HIV serostatus, antiretrovi-
ral therapy, and pre-ART CD4 cell count for those who had
initiated therapy, with CMIA negative samples. All samples
were then assayed blinded for the presence of XMRV plasma
RNA and proviral DNA in PBMCs using highly sensitive
XMRV qPCR assays (X-SCA) (Kearney et al. submitted in
press).
2.2. XMRV Chemiluminescent Immunoassays (CMIAs) and
Western Blot. A detailed procedure has been described pre-
viously [15]. Brieﬂy, 100μL of neat plasma were screened for
antibodies to XMRV gp70 (SU) and p15E (TM) proteins
using two prototype ARCHITECT chemiluminescent im-
munoassays (CMIAs; Abbott Diagnostics, Abbott Park, IL).
The CMIAs utilize a direct assay format in which E. coli-ex-
pressed XMRV p15E or mammalian-expressed XMRV gp70
was used as both capture and detection antigens. Assay posi-
tivecontrolswerederivedfromXMRV-infectedrhesusmaca-
queplasmaat1:1000(PC1)or1:4000(PC2).Apoolofnor-
malhumanplasmawasusedasnegativecontrol(NC).C utoﬀ
(CO)valuesoftheARCHITECT CMIAswerecalculatedbas-
ed on the following formulas: CO = 0.45 × (PC2 Mean Rela-
tive Light Units (RLU)) for p15E CMIA and CO = 0.078 ×
(PC1 Mean RLU) for gp70 CMIA. Assay results were report-
ed as the ratio of the sample RLU to the cutoﬀ RLU (S/CO)
for each specimen. Specimens with S/CO values <1.00 were
considered nonreactive; specimens with S/CO values >1.00
were considered initially reactive. Reactive specimens were
further analyzed by ARCHITECT p30 CMIA and by inves-
tigational western blot assays.
ARCHITECT p30 CMIA also utilizes the direct assay
format with E. coli-expressed XMRV p30 (capsid protein) to
capture and detect anti-p30 antibodies [15] .T h es a m es a m -
ple volume (100μL), calibrator, and controls were used for
the p30 CMIA. CO of p30 CMIA was calculated based on the
formula: CO = 0.27 × (PC1 Mean RLU).
Western blot (WB) analysis using puriﬁed XMRV viral
lysate as well as recombinant gp70 protein was performed as
described[15].Brieﬂy,virallysate(65μg/gel)orrecombinant
gp70 protein (25μg/gel) was separated by electrophoresis on
a 4–12% NuPAGE Bis-Tris 2-dimension gel (Invitrogen,
Carlsbad, CA) in the presence of sodium dodecylsulfate
(SDS). The protein bands on the gel were electrophoretically
transferred to a polyvinylidene diﬂuoride (PVDF) mem-
brane(Invitrogen).Afterblocking,thePVDFmembranewas
cut into 2mm strips. Strips were incubated with human
plasma samples diluted 1:100 or XMRV-infected macaque
plasma [18] diluted 1:250 overnight at 2–8◦C. After removal
of unbound antibodies, strips were incubated with alkaline
phosphatase conjugated goat antihuman IgG (Southern Bio-
tech, Birmingham, AL) for 30 minutes at room temperature.Advances in Virology 3
The strips were washed, and chromogenic substrate solution
was added to visualize the reactive bands.
2.3. Nucleic Assay Detection with XMRV Single-Copy Assays
(X-SCA). SimilartotheHIV-1single-copyassay(SCA)[19],
real-time PCR and RT-PCR assays for detection of XMRV,
called X-SCA (XMRV single-copy assay), were developed to
quantifyXMRVRNAinplasmaandproviralDNAinPBMCs
(Kearney et al. in press). X-SCA was designed using ampli-
ﬁcation primers targeting a conserved gag leader region bet-
ween XMRV and endogenous MLVs allowing detection of
both templates. The TaqMan probe was designed to span the
signature 15–24nt deletion (derived from PreXMRV-2 [14]
in the XMRV gag leader region compared to other MLV seq-
uences). This probe design results in a lower plateau level of
ﬂuorescence from non-XMRV templates than from XMRV
templates, thus distinguishing the source of product that is
being detected in the assay (Kearney et al. in press). To con-
ﬁrm any positive result, PCR products are run on a 2% aga-
rose gel, allowing distinction between the 86nt XMRV X-
SCA product and the 110nt non-XMRV product.
Patient samples from the MACs cohort were tested by X-
SCA in triplicate with equal numbers of no template controls
(NTC) to monitor the level of false positives due to common
mouse genomic DNA contamination. An internal RCAS
(avian retrovirus) control was spiked into each plasma sam-
ple to quantify nucleic acid recovery from plasma samples as
described previously [19]. X-SCA was performed on 0.1-
0.2mL of plasma resulting in a limit of detection of 9–18
RNAcopies/mLandon1 ×106 PBMCsresultinginalimitof
detection of 1 DNA copy/1 × 106 cells.
2.4. CriteriaforDetermining XMRV Infection Status. There is
ahighriskofobtainingfalsepositiveresultsfromCMIAsand
PCR diagnostic tests [9, 10] .T h e r e f o r e ,w es e ts t r i c tc r i t e r i a
for declaring a sample positive for XMRV. We required that
the sample must test positive for both XMRV antibody by
CMIAs or Western blot and nucleic acid (either RNA or
DNA) by X-SCA. A positive X-SCA test required detection of
virusinalltriplicatePCRreactions.Ifdiscordantresultswere
obtained from triplicate wells, then the result was considered
indeterminate.
2.5. Data Analysis and Sample Size Calculations. The sample
sizes of 200 HIV-1-seropositive and 200 seronegative partici-
pants initially were chosen with arcsine approximation to
provide 86% power to detect a diﬀerence in XMRV preva-
lence assuming 12% XMRV prevalence in HIV-1 seroposi-
tives versus 4% in seronegatives, with α = 0.05. The 4% rate
among HIV-1 seronegatives corresponded to the 3.7% pre-
valence observed in published control series [1]. Selection of
HIV-1-seropositive men in the current ART era limited the
inclusion of ART-na¨ ıve men, and the need for unthawed
PBMC pellets and EDTA plasma further reduced the sample
sizeto332.Giventhesmallnumberofpositiveresults,simple
frequencies are used to describe the data.
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Figure 1: XMRV Western Blot Analysis. WB analysis of CMIA
reactive MACS subjects using native XMRV viral lysate and recom-
binant gp70 protein. XMRV-infected macaque plasma was used as
positivecontrol(PC).Sample222testedpositiveforp15EbyCMIA;
all the others were positive for gp70 (Table 1).
3. Results
3.1. XMRV Serology with ARCHITECT CMIAs and Western
Blot. Using the direct format ARCHITECT p15E and gp70
CMIAs, XMRV serology was evaluated on 332 recently
collected plasma samples from patients in the MACS cohort.
Nine samples (5 HIV-1 seropositive, 4 HIV-1 seronegative)
were found to be reactive to XMRV proteins, one against the
p15E transmembrane protein and 8 against the gp70 enve-
lope protein (Table 1), resulting in a frequency of 0.3%
(1/332)positiveforp15Eand2.4%(8/332)forgp70.Ofnote,
however,noneofthesampleswerereactiveagainstbothp15E
and gp70. Subsequent testing of the 9 positive samples with
the p30 CMIA showed no detectable anti-p30 antibodies
(Table 1).
By viral lysate WB, the only p15E CMIA-positive sample
222 was reactive to native p15E protein (Table 1, Figure 1).
However, only 1 of the 8 gp70 CMIA-positive samples (215)
wasreactiveintherecombinantgp70WB.Thelowconﬁrma-
tion rate could be due to higher sensitivity of the gp70 CMIA
or the antibodies detected may primarily recognize confor-
mationalepitopeswhichweresensitivetoSDSorthermalde-
naturation. Although nonreactive in p30 CMIA, two sam-
ples,222and227hadanapparentp30bandinthevirallysate
WB (Table 1, Figure 1). However, subsequent WB analysis of
CMIA-negative normal blood donors showed the presence
of p30 band indicative of nonspeciﬁcity or cross-reactivity
(data not shown). Others have also observed the nonspeciﬁc
reactivity against XMRV p30 protein in WB [20].
3.2. Nucleic Assay Detection with XMRV Single-Copy Assays
(X-SCA). XMRV single-copy assays (X-SCA) were conduc-
ted on both plasma and PBMCs from the 9 patients with
CMIA-reactive antibodies, and 25 CMIA-negative controls4 Advances in Virology
Table 1: XMRV antibody reactivity for the MACS Subjects.
MACS ID
CMIA (S/CO)
WB
p15E
TM
gp70
SU
p30∗
CA
222 1.67 0.08 0.23 p15E+, p30+
217 0.22 28.48 0.17
229 0.18 8.73 0.19
215 0.17 21.36 0.21 gp70+
227 0.20 2.27 0.18 p30+
231 0.17 1.56 0.18
210 0.18 1.65 0.22
211 0.17 1.47 0.20
233 0.19 1.80 0.20
Control
NC 0.17 0.11 0.23
PC1 7.90 12.82 3.70 gp70+, p15E+, p30+
PC2 2.22 3.47 1.10 NA
∗Samples were tested at 1:2.5–5 dilutions due to limited sample volume.
matched for date of MACS entry, HIV serostatus, ART use,
time from ART initiation, and pre-ART CD4+ T-cell count
(Table 2). None of the samples tested were found to be posi-
tive for XMRV nucleic acid by X-SCA (either RNA or DNA)
including the 9 samples that were CMIA reactive. Given the
sample volumes available for testing, X-SCA had limits of
detection for XMRV RNA in plasma of 9.2 copies/mL and 1
XMRVDNAcopyinonemillionPBMCs.Sixty-onecopiesof
RNA were detected in one of triplicates from sample 218,
resulting in an indeterminate X-SCA result for this subject.
The same sample was CMIA nonreactive, and no XMRV
DNA was detected in one million PBMCs. Consequently, the
sample did not meet our criteria for a positive XMRV result.
A single positive well in an X-SCA run is not above the level
of false positives for XMRV real-time PCR assays due to the
high frequency of environmental mouse genomic DNA that
readily ampliﬁes with the X-SCA primers (Kearney et al. in
press).
4. Discussion
The XMRV study by Lombardi et al. published in October
2009 suggesteda surprisingly high seroprevalenceforXMRV,
even among healthy control subjects [1]. Therefore, we set
out to evaluate the prevalence of XMRV infection in a possi-
ble high-risk cohort. We adopted a multiple diagnostic assay
approach to determine the XMRV status of patient samples
to minimize the possibility of obtaining false positive results
by individual molecular or serologic methods. False positive
PCR results may occur from incidental ampliﬁcation of en-
vironmental mouse genomic DNA due to the close relation-
shipbetweenXMRVandmouseproviruses[9,10].Falsepos-
itive serology results may occur due to nonspeciﬁc or cross-
reactive human antibodies [15]. In fact, a recent study re-
ported that ∼4% of HTLV-I-infected individuals had anti-
bodies that were cross-reactive to XMRV p15E protein [21].
Therefore, we applied stringent criteria for XMRV positivity
aimed at limiting the risk of reporting false positive results.
Our criteria for an XMRV infection required that (1) all re-
plicatesfromX-SCAmustbepositive,(2)antibodiesmustbe
detectablebyCMIAand/orWesternblot,and(3)nucleicacid
andantibodymustbothbepositive.Samplesresultingindis-
cordant results from X-SCA replicates were reported as in-
determinate. Applying these criteria, we did not identify any
samples from the MACS cohort that were consistent with
XMRV infection. Nine samples had positive serology, but no
detectable XMRV nucleic acid. Although one sample was
indeterminate for XMRV RNA by X-SCA, it was antibody
negative. XMRV DNA was not detected in any sample tested.
Because we did not ﬁnd any patient to be reactive to multiple
XMRV antigens and because all nine patients for whom
serum reactivity was observed were negative for XMRV
nucleic acid, we concluded that follow-up testing by addi-
tional methods, such as virus culture, was not necessary. We
believe that the combined approach of sensitive antibody
screening and sensitive and speciﬁc nucleic acid testing ex-
cludes XMRV infection in the cohort studied.
Previous studies have shown that X-SCA is able to detect
XMRVRNAandDNAinspikedcontrolsamplesandinspec-
imens from inoculated macaques with high sensitivity [22]
(Kearney et al. in press; Del Prete et al. in preparation). In the
samplesanalyzedhere,thesensitivityfordetectionwaslimit-
ed by the small sample volumes available for testing. Despite
this, the limits of detection were still adequate to detect
XMRV DNA that has been shown to persist in macaque
PBMCsamplesfollowingXMRVinfection (DelPreteet al.in
preparation). Consequently, proviral DNA would likely have
been detectable in any subject recently infected with XMRV.
It has been argued that XMRV nucleic acid could be missed
in clinical samples from infected individuals due to low-level
or episodic viremia. By testing a large cohort of HIV-infected
individuals for immunity to XMRV and not for viral nucleic
acid alone, we reduced the risk of reporting false negatives
for XMRV infection.
Despite earlier reports that evidence of XMRV infection
was detected in about 20% of prostate cancer patients [2, 23–
25] and 67% of CFS patients [1], we did not ﬁnd clear evi-
dence for XMRV infection in a cohort of men with HIV-1
infectionorathighriskforHIV-1infection.Theseresultsare
consistent with prior reports that failed to detect XMRV
nucleic acid in HIV-1-infected patients [7, 16, 17, 26].
Findings from previous studies reporting higher preva-
lence for XMRV infection in cohorts typically involved test-
ing by a single diagnostic method. In the current study, if we
had based XMRV infection on a single diagnostic method
(either PCR or serology), the apparent XMRV prevalence
would have been 1.2%; 0.3% (1/332) by PCR and 0.9%
(3/332) by serology. Given the potential for false positive re-
sults in PCR and serological assays for XMRV, our results
suggest that applying multiple diagnostic methods including
measuring levels of proviral DNA in blood cells provides a
more reliable approach for investigating the prevalence of
XMRV infection. We hypothesized that the prevalence of
XMRV infection would be higher among men who have ac-
quired HIV-1 infection than among seronegative controls.Advances in Virology 5
Table 2: XMRV nucleic acid and antibody results.
Subject ID XMRV average RNA
copies/mL by X-SCA
XMRV DNA copies per 1e6
cells by X-SCA
ARCHITECT
antibody serology Western blot XMRV status
201 <10 <1 neg NT neg
202 <10 <1 neg NT neg
203 <10 <1 neg NT neg
204 <9 <1 neg NT neg
205 <18 <1 neg NT neg
206 <9 <1 neg NT neg
207 <9 <1 neg NT neg
208 <9 <1 neg NT neg
209 <9 <1 neg NT neg
210 <9 <1 gp70+ neg neg
211 <9 <1 gp70+ neg neg
212 <9 <1 neg NT neg
213 <9 <1 neg NT neg
214 <9 <1 neg NT neg
215 <18 <1 gp70+ gp70+ neg
216 <9 <1 neg NT neg
217 <9 <1 gp70+ neg neg
218 61 <1 neg NT neg
219 <9 <1 neg NT neg
220 <9 <1 neg NT neg
221 <9 <1 neg NT neg
222 <9 <1 p15E+ p15E+, p30+ neg
223 <9 <1 neg NT neg
224 <9 <1 neg NT neg
225 <9 <1 neg NT neg
226 <9 <1 neg NT neg
227 <9 <1 gp70+ p30+ neg
228 <9 <1 neg NT neg
229 <9 <1 gp70+ neg neg
230 <9 <1 neg NT neg
231 <9 <1 gp70+ neg neg
232 <9 <1 neg NT neg
233 <9 <1 gp70+ neg neg
234 <9 <1 neg NT neg
∗NT indicates that MACS ID was not tested by Western blot assay.
The negative data from our study clearly refute this hypothe-
sis.IndividualsatriskforHIV-1infectionandsexuallytrans-
mitted infections are not at risk for XMRV infection.
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